Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 2/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | RHOC | P08134 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atorvastatin Lactone SCHEMBL13762456 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| Atorvastatin Lactone SCHEMBL1266 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| Atorvastatin Lactone SCHEMBL1258955 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| Atorvastatin Lactone SCHEMBL12060138 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| Atorvastatin Lactone SCHEMBL12648491 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| Atorvastatin Lactone SCHEMBL1265 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| Atorvastatin Lactone SCHEMBL9810905 | 0.97 | HMGCR (0.94) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| SCHEMBL5605464 | 0.96 | HMGCR (0.93) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| SCHEMBL5605468 | 0.96 | HMGCR (0.93) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| SCHEMBL13992376 | 0.96 | HMGCR (0.93) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210169838-A1 | Novel class of compounds for the treatment of cardiovascular disease. | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2021-06-10 | — | — | US | disclosed |
| US-20210169838-A1 | Novel class of compounds for the treatment of cardiovascular disease. | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2021-06-10 | — | — | US | disclosed |
| US-20190038588-A1 | NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2019-02-07 | — | — | US | disclosed |
| US-20190038588-A1 | NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2019-02-07 | — | — | US | disclosed |
| WO-2017137469-A1 | NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2017-08-17 | — | — | WO | disclosed |
| US-20120046335-A1 | SOLID STATES OF ATORVASTATIN POTASSIUM | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2012-02-23 | — | — | US | disclosed |
| US-20120046335-A1 | SOLID STATES OF ATORVASTATIN POTASSIUM | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2012-02-23 | — | — | US | disclosed |
| US-8071638-B2 | Solid states of atorvastatin potassium | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-12-06 | — | — | US | disclosed |
| US-8071638-B2 | Solid states of atorvastatin potassium | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-12-06 | — | — | US | disclosed |
| US-20100041731-A1 | SOLID STATES OF ATORVASTATIN POTASSIUM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-02-18 | — | — | US | disclosed |
| US-20100041731-A1 | SOLID STATES OF ATORVASTATIN POTASSIUM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-02-18 | — | — | US | disclosed |
| US-20090018182-A1 | Crystalline forms of atorvastatin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-01-15 | — | — | US | disclosed |
| US-20090018182-A1 | Crystalline forms of atorvastatin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018182-A1 | Crystalline forms of atorvastatin | HMGCR, LIPA, ACAT2 | HMGCR 1/4885SLCO1B1 409/4885ABCB1 2283/4885 |
| US-20100041731-A1 | SOLID STATES OF ATORVASTATIN POTASSIUM | HMGCR, PCSK9, APOB | HMGCR 1/4885SLCO1B1 265/4885ABCB1 425/4885 |
| US-20190038588-A1 | NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | FABP3, TNNI3, TNNT2 | HMGCR 18/4885SLCO1B1 3158/4885ABCB1 672/4885 |
| US-20210169838-A1 | Novel class of compounds for the treatment of cardiovascular disease. | FABP3, TNNI3, TNNT2 | HMGCR 16/4885SLCO1B1 3185/4885ABCB1 476/4885 |
| US-20120046335-A1 | SOLID STATES OF ATORVASTATIN POTASSIUM | HMGCR, PCSK9, APOB | HMGCR 1/4885SLCO1B1 265/4885ABCB1 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.